Prevention Of Cancer Of Uterus / Cervical Cancer With The Human Papilloma Virus

The HPV virus has gone unseen by many until the recent controversy over the vaccine. However, this virus is thought to be one of the world’s most wide spread STD’s. “According to the Centers for Disease Control and Prevention (CDC), about 6.2 million women and men are newly infected every year” with HPV. HPV has over 100 strains, with more than thirty that are sexually transmitted. Some of these strains are known to cause cervix, vulva, vagina, anus, or penis cancers and others can cause genital warts. “Studies have found the vaccine to be almost 100% effective in preventing diseases caused by the four HPV types covered by the vaccine—including precancers of the cervix, vulva and vagina, and genital warts” (“HPV Questions and

Prophylactic vaccination against high risk human papilloma virus 16 and 18 represents an exciting means of protection against HPV related malignancy. However, this strategy alone, even if there is a level of cross protection against other oncogenic viruses, cannot completely prevent cervical cancer. In some countries cervical screening programs have reduced the incidence of invasive cervical cancer by up to 80 percent although this decline has now reached a plateau with current cancers occurring in patients who have failed to attend for screening or where the sensitivity of the tests have proved inadequate. Cervical screening is inevitably associated with significant anxiety for the many women who require investigation and treatment following abnormal cervical cytology. However, it is vitally important to stress the need for continued cervical screening to complement vaccination in order to optimize prevention in vaccines and prevent cervical cancer in older women where the value of vaccination is currently unclear. It is likely that vaccination will ultimately change the natural history of HPV disease by reducing the influence of the highly oncogenic types HPV 16 and 18. In the long term this is likely to lead to an increase in recommended screening intervals. HPV vaccination may also reduce

Human papillomavirus (HPV) infection is a widespread sexually transmitted infection. Approximately 14 million Americans are infected with HPV each year ("HPV Vaccine for Preteens and Teens,"). HPV also causes several types of cancers, such as vaginal cancer and anal cancer. More than 27,000 women and men are affected by a HPV-related cancer annually ("The Link Between HPV and Cancer,"). The most common HPV cancers for women and men are cervical cancer, and oral cavity and oropharyngeal cancers, respectively. Research has demonstrated that many cancers caused by HPV can be prevented by the HPV vaccine, which is administered in 3 doses over 6 months ("The

The controversial debate regarding the safety of vaccinations continues to captivate the masses; however we must understand whether the side effects from the vaccine outweigh the risk of the disease it may prevent. There is only one way to prevent the disease cervical cancer, and that is through examination, not vaccination. The vaccination available to aid in prevention of cervical cancer has some effectiveness and in many cases ineffectiveness, in preventing Human Papillomavirus. In essence, the most reliable method of prevention is regular visits with your physician.

The Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI). There are over 100 types of HPV, but only 40 types affect the genital area and can cause genital warts and cervical cancer in women (“Human Papillomavirus (HPV) Vaccine”). In 2011 in the United States, 12,109 women were diagnosed with cervical cancer. Of those, 4,092 women died (“Cervical Cancer Statistics”). HPV is not only contracted from sexual intercourse, but also from skin to skin contact, including oral sex. The STI affects males and females involved in both homosexual and heterosexual sexual activities. Over 70 percent of sexually active individuals contract and carry HPV before the age of 80. In order to combat HPV two different brands of HPV vaccination – Gardasil and Cervarix – were created. Both include a vaccination plan of three shots over the course of six months. Gardasil was created by Merck & Co., and was licensed by the FDA in June 2006. The vaccine protects against HPV types 16 and 18, which lead to cervical cancer, as well as types 6 and 11, which cause 90% of genital warts. The FDA later approved Cervarix, created by GlaxoSmithKline, in 2009, which only protects against HPV types 16 and 18 (“Human Papillomavirus (HPV) Vaccine”). Originally, Gardasil was only approved for females, but three years after the release, the vaccine was approved

Cervical cancer is a type of abnormal and malignant cell growth on the cervix (birth canal), which causes the common death for American Women. Infected by Human Papillomavirus (HPV) through sexual contact is the main contributor to cervical cancer. According to American Cancer Society’s (ACS) (2017) estimation, around 12,820 people will newly have cervical cancer and about 4,210 people will die from that in 2017. Therefore, it is urgent to decrease the rate of cervical cancer at women. A three-shot Gardasil series vaccine approved by the FDA for girls started to prevent cervical cancer in 2006. There are more than forty types of HPVs and the majority

The human papillomavirus remains one of the highest common sexually transmitted infections in the United States. The human papillomavirus dates back to the nineteen hundreds. Scientists during the nineteen hundreds did not comprehend on why people who had sexually transmitted infections also had cancer. It was not until the nineteen-eighties, that a scientist discovered that the human papilloma virus caused cancer (Preventing Cervical Cancer). Moreover the human papillomavirus causes genital warts in both men and women. In the year two thousand and six, a scientist generated two vaccines that protect the human body from contracting the virus. The Food and Drug Administration approved Gardasil and Cervarix since they are clinically tested

Human Papillomavirus is a sexually transmitted disease that infects over twenty million Americans each year (Vanslyke, Baum, Plaza, Otero, Wheeler, Helizter, 2008, P. 584). Many of these people do not realize that they are infected because they do not show any symptoms. Even though HPV has been talked about for decades, it is only until recent years that the topic has become part of mainstream women’s health issues. Not only that, many of these people are women who do not understand the importance of testing for HPV. HPV is one of the leading causes of cervical cancer among women.

Human Papilloma Virus (HPV) is a double stranded DNA virus. There are many genotypes HPV and some of them are oncogenic. They have envelope proteins E6 and E7 on their cell wall which are associated to initiate cancer. Anogenital lesions associated to HPV are divided into ‘low-risk’ types (6, 11, 34, 40, 42, and 43) and ‘high risk’ types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 73, and 82). Most of the low risk HPV infections are asymptomatic and are not fatal, however infection to high risk HPV such as type 16 and 18 may cause cervical, anal, vaginal, vulvar and penile cancer (Centre of Disease Control, 2012). Low risk HPV generally cause warts on the skin surface which rarely develop into malignancy. Type 16 and 18 both were originally isolated from cervical carcinomas of human body. More than 70% of human cervical is due to the infection of either HPV 16 or 18. According to CDC, in 2008 it was estimated 11,070 cases of cervical cancer in United States and about 3,870 deaths due to cervical cancer. Higher percentage of HPV persistent infection occurs by HPV-16 and the risk of getting cervical cancer due the progression of disease is higher for HPV 16 and 18 and 45 (Tino F. Schwarz, 2008).

Human Papilloma Virus (HPV) is the most commonly diagnosed sexually transmitted infection in the United States (Ault, 2006). Almost all sexually active men and women will contract HPV at least once during their lifetime (What is HPV?, 2015). Sexually active women below the age of twenty-five consistently have the highest rates of infection (Ault, 2006). The development of the HPV vaccine in 2006 has decreased the prevalence of infection from 11.5% to 5.1% among females ages 14 to 19 (CDC, 2015). High-risk strains of HPV are also “detected in 99% of cervical cancer cases” (Valdez, Stuart, Tanjasari, Levy, & Garza, 2015, p. 106). Therefore HPV infection is one of the most significant risk factors in the development of cervical cancer.

The advent of new human papilloma virus (HPV) vaccines with the potential to prevent the majority of cases of invasive cervical cancer presents a remarkable public health achievement (Markowitz et al., 2007). This is because cervical cancer is the commonest female cancer worldwide and it has been associated with HPV infection (Franceschi et al., 2009). In just 2015, there will be 12,900 new cases of cervical cancer in the United States with 4,100 estimated deaths (Siegel, Miller, & Jemel, 2015).

In June 2006, pharmaceutical company Merck licensed the human papillomavirus (HPV) vaccine, Gardasil, for both males and females. The Advisory Committee on Immunization Practices (ACIP) recommended that this vaccine be administered to females, starting at 11 or 12 years old. According to the MMWR, "genital human papillomavirus (HPV) is the most common sexually transmitted infection in the United States; an estimated 14 million persons are newly infected each year" (Markowitz et al., 2014). The Healthy People 2020 plan released four goals (STD-9, 9.1, 9.2 and 9.3) related to reducing the proportion of females with HPV, particularly types 6, 11, 16 and 18. It is hypothesized that the HPV vaccination can prevent HPV strains, particularly those that are underlying factors of cancer. This literature review attempts to

Cervical cancer is the second foremost occurring cancer in women after breast cancer. Cervical cancer is a sexually transmitted disease caused by the human papillomavirus, or HPV. Infection by HPV typically occurs in the early years of sexual activity according to the World Health Organization (WHO), but it can take up to a full twenty years for it to develop into a full-blown malignant tumor. Scientists believe that for all intents and purposes all cervical cancer cases are caused by infection with a few types of cancer. Great strides have been made in recent years in the development of a vaccine to treat the cervical cancer. Scientists have cultivated a prophylactic vaccine that would protect against the human papillomavirus. HPV's

Among the many arguments for mandatory HPV vaccination, the foremost is that it is an important medical achievement and a major public health milestone. This vaccine has proven to be one-hundred percent effective in preventing the 4 HPV strains that are responsible for seventy percent of cervical cancers and ninety percent of genital warts. In addition, no serious side effects have been identified. Because this vaccine is a preventive measure, administration before onset of sexual activity is ideal; however, even females who have been sexually active can still benefit from this vaccination (Perkins et al., 2010). Nationally and internationally, the HPV vaccine will significantly reduce disease burden by reducing monetary and psychological costs of invasive procedures that remove precancerous and cancerous lesions. By combining vaccination with routine Pap smear screening, these public health efforts have the remarkable opportunity to eradicate cervical cancer (Ramet et al., 2011).

Cervical cancer is second among the most common cancer that affects women globally. The challenge towards the measures taken to reduce the disease among women is the lack of proper information on the link between the disease itself and the leading cause of it. The disease can be reduced by limiting sexual partners and practicing safe sex, which are challenging and difficult to promote. Therefore, one of the effective ways towards reducing the various cases of cervical cancer is through the HPV vaccination. Most women do not have the information on the connection between cervical cancer and HPV. Consequently, there is the uncertainty among women